Business Context and Reporting Period
This Form 8-K is a current report filed by AcelRx Pharmaceuticals, Inc. (not TalpherA, Inc. as noted in metadata) on October 8, 2015. The registrant is a Delaware corporation headquartered in Redwood City, California. The filing serves to disclose a regulatory update regarding the company's product candidate, Zalviso.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a specific event and does not contain financial statements or performance metrics.
Material Changes
The material event reported is the issuance of a press release on October 8, 2015, providing a regulatory update on Zalviso. No financial changes or comparative period data are included in this document.
Guidance, Outlook, and Risks
The filing references a press release (Exhibit 99.1) containing the regulatory update but does not include the text of that release, specific management commentary, forward-looking guidance, or a detailed discussion of risks within the body of this Form 8-K.
Investor Verification Checklist
- Verify the specific details of the regulatory update for Zalviso by reviewing Exhibit 99.1 (Press Release dated October 8, 2015).
- Confirm the company name is AcelRx Pharmaceuticals, Inc. and not TalpherA, Inc.
- Review the company's most recent 10-Q or 10-K for financial metrics, as this 8-K contains none.